Florian Nima Fleckenstein

Dr. Florian Nima Fleckenstein

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2022 in Journal of Orthopaedic Research
Verified
Journal Article
Open access
SZSijia Zhou
Sijia Zhou
TMTazio Maleitzke
Tazio Maleitzke
SGSven Geissler
Sven Geissler
AHAlexander Hildebrandt
Alexander Hildebrandt
FFFlorian Nima Fleckenstein
Florian Nima Fleckenstein
Tobias WinklerTobias Winkler
Tobias Winkler
Knee osteoarthritis, the most prevalent degenerative joint disorder worldwide, is driven by chronic low‐grade inflammation and subsequent cartilage degradation. Clinical data on the role of the Hoffa or infrapatellar fat pad in knee osteoarthritis are, however, scarce. The infrapatellar fat pad is a richly innervated intracapsular, extrasynovial adipose tissue, and an abundant source of adipokines and proinflammatory and catabolic cytokines, which may contribute to chronic synovial inflammation, cartilage destruction, and subchondral bone remodeling during knee osteoarthritis. How the infrapatellar fat pad interacts with neighboring tissues is poorly understood. Here, we review available literature with regard to the infrapatellar fat pad's interactions with cartilage, synovium, bone, menisci, ligaments, and nervous tissue during the development and progression of knee osteoarthritis. Signaling cascades are described with a focus on immune cell populations, pro‐ and anti‐inflammatory cytokines, adipokines, mesenchymal stromal cells, and molecules derived from conditioned media from the infrapatellar fat pad. Understanding the complex interplay between the infrapatellar fat pad and its neighboring articular tissues may help to better understand and treat the multifactorial pathogenesis of osteoarthritis.

1 June 2017 in Radiology
Verified
Journal Article
Closed access
SSSonia Sahu
Sonia Sahu
RSRuediger Schernthaner
Ruediger Schernthaner
RARoberto Ardon
Roberto Ardon
JCJulius Chapiro
Julius Chapiro
YZYan Zhao
Yan Zhao
RDRafael Duran
Rafael Duran
Volumetric enhancing tumor burden is an early treatment response biomarker and surrogate for survival in patients with multifocal, bilobar neuroendocrine liver metastases after the first transarter... PurposeTo investigate whether whole-liver enhancing tumor burden [ETB] can serve as an imaging biomarker and help predict survival better than World Health Organization (WHO), Response Evaluation C...

1 May 2017 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
JSJae Ho Sohn
Jae Ho Sohn
RDRafael Duran
Rafael Duran
YZYan Zhao
Yan Zhao
FFFlorian Nima Fleckenstein
Florian Nima Fleckenstein
JCJulius Chapiro
Julius Chapiro
JGJean-Francois Geschwind
Jean-Francois Geschwind

1 December 2016 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PDF file
YZYan Zhao
Yan Zhao
RDRafael Duran
Rafael Duran
JCJulius Chapiro
Julius Chapiro
JSJae Ho Sohn
Jae Ho Sohn
SSSonia Sahu
Sonia Sahu
JGJean-François Geschwind
Jean-François Geschwind

10 April 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Iason PsilopatisIason Psilopatis
Iason Psilopatis
Nikolaos GarmpisNikolaos Garmpis
Nikolaos Garmpis
AGANNA GARMPI
ANNA GARMPI
KVKleio Vrettou
Kleio Vrettou
Panagiotis SarantisPanagiotis Sarantis
Panagiotis Sarantis
Christos DamaskosChristos Damaskos
Christos Damaskos
Cervical carcinoma is one of the most common cancers among women globally. Histone deacetylase inhibitors (HDACIs) constitute anticancer drugs that, by increasing the histone acetylation level in various cell types, induce differentiation, cell cycle arrest, and apoptosis. The aim of the current review is to study the role of HDACIs in the treatment of cervical cancer. A literature review was conducted using the MEDLINE and LIVIVO databases with a view to identifying relevant studies. By employing the search terms “histone deacetylase” and “cervical cancer”, we managed to identify 95 studies published between 2001 and 2023. The present work embodies the most up-to-date, comprehensive review of the literature centering on the particular role of HDACIs as treatment agents for cervical cancer. Both well-established and novel HDACIs seem to represent modern, efficacious anticancer drugs, which, alone or in combination with other treatments, may successfully inhibit cervical cancer cell growth, induce cell cycle arrest, and provoke apoptosis. In summary, histone deacetylases seem to represent promising future treatment targets in cervical cancer.

13 January 2016 in European Radiology
Verified
Journal Article
Closed access
PDF file
FFFlorian Nima Fleckenstein
Florian Nima Fleckenstein
RSRüdiger E. Schernthaner
Rüdiger E. Schernthaner
RDRafael Duran
Rafael Duran
JSJae Ho Sohn
Jae Ho Sohn
SSSonia Sahu
Sonia Sahu
JCJulius Chapiro
Julius Chapiro